Research programme: fusion protein biosimilars - Alvotech
Latest Information Update: 28 Dec 2023
At a glance
- Originator Alvotech
- Class Anti-inflammatories; Antineoplastics; Recombinant fusion proteins
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Autoimmune disorders; Cancer; Inflammation
Most Recent Events
- 28 Dec 2023 No recent reports of development identified for research development in Autoimmune-disorders in Iceland
- 28 Dec 2023 No recent reports of development identified for research development in Cancer in Iceland
- 28 Dec 2023 No recent reports of development identified for research development in Inflammation in Iceland